α-lipoic amide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二硫杂环戊烷
• 英文名称: α-lipoic amide
• 英文别名: (R)-lipoamide；lipoamide；(R)-5-(1,2-dithiolan-3-yl)pentanamide；5-[(3R)-dithiolan-3-yl]pentanamide
• 化学式: C₈H₁₅NOS₂
• 分子量: 205.345
• InChiKey: FCCDDURTIIUXBY-SSDOTTSWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  12
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  93.7
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  R-(+)-硫辛酸 、 N-羟基丁二酰亚胺 、 1,2-二氯乙烷 在 水 、 碳酸氢钠 、 氯化钠 、 magnesium sulfate 作用下， 以 二氯甲烷 、 乙酸乙酯 为溶剂， 反应 16.0h， 生成 α-lipoic amide
  参考文献：
  名称：

  Methods of treating ocular diseases using derivatives of lipoic acid

  摘要：

  本文公开了使用二硫醇化合物及其衍生物和药学上可接受的盐治疗眼部疾病的方法。特别地，本文描述了使用含有硫辛酸衍生物的二硫醇化合物的方法。这些二硫醇化合物特别适用于治疗老视和白内障等眼部疾病。

  公开号：

  US08795706B2

文献信息

• Alternative energy substrates
  申请人：KABIVITRUM AB

  公开号：EP0366632A1

  公开（公告）日：1990-05-02

  Compounds of the general formula A - B where A is a carboxylic acid group having a carbon chain of 3-10 carbon atoms and preferably being branched, and which includes one or more oxo groups, and B is hydro­gen, a pharmaceutically acceptable metal atom, an al­cohol bound as ester and having 1-5 carbon atoms and 1-3 hydroxy groups, or a glycerol group bound as ester, can be used as a nutrient substrate, an antimicrobial and antiviral agent, and/or as an agent for influencing the central nervous system. The invention also relates to compositions intended for the aforementioned usages and containing at least one compound A - B.

  一般公式为 A - B 的化合物 其中 A 是一个具有 3-10 个碳原子的碳链的羧酸基团，最好是分支的，并且包括一个或多个氧代基团，B 是氢，一种药物上可接受的金属原子，一个作为酯键合的醇，有 1-5 个碳原子和 1-3 个羟基，或一个作为酯键合的甘油基团，可以用作营养底物，抗菌和抗病毒剂，以及/或作为影响中枢神经系统的剂。 该发明还涉及旨在上述用途并含有至少一个化合物 A - B 的组合物。
• Compositions and Methods for Preventing or Treating Diseases, Conditions, or Processes Characterized by Aberrant Fibroblast Proliferation and Extracellular Matrix Deposition
  申请人：MOERAE MATRIX, INC.

  公开号：US20160136234A1

  公开（公告）日：2016-05-19

  The described invention provides compositions and methods for reducing progression of a fibrosis in a tissue of a subject selected from liver, kidney or vascular fibrosis, the progression of the fibrosis being characterized by aberrant fibroblast proliferation and extracellular matrix deposition in the tissue. The method includes administering a therapeutic amount of a pharmaceutical composition containing a polypeptide having the amino acid sequence YARAAARQARAKALARQLGVAA (SEQ ID NO: 1) or functional equivalent thereof, and a pharmaceutically acceptable carrier, wherein the therapeutic amount of the polypeptide is effective to reduce progression of the fibrosis, to treat remodeling of the tissue, or a combination thereof.

  描述的发明提供了一种用于减少主体选定组织中的纤维化进展的组成和方法，该选定组织来自肝纤维化、肾纤维化或血管纤维化，纤维化的进展在组织中以异常成纤维细胞增殖和细胞外基质沉积为特征。该方法包括施用含有具有氨基酸序列YARAAARQARAKALARQLGVAA（SEQ ID NO: 1）或其功能等效物的多肽的药物治疗量，以及药学上可接受的载体，其中多肽的治疗量有效于减少纤维化的进展，治疗组织的重塑，或其组合。
• Process for Preparation of Hexadecyl Cis-9-Tetradecenoate and Hexadecyl Cis-10-Tetradecenoate
  申请人：Bethala Lakshmi Anu Prabhavathi Devi

  公开号：US20110269987A1

  公开（公告）日：2011-11-03

  Hexadecyl cis-9-tetradecenoate commonly known as Cetyl myristoleate (CMO) is being used for the treatment of osteoarthritis and other joint inflammatory diseases, cis-9-Tetradecenoic acid (cis-9-myristoleic acid) is the main precursor for the preparation of CMO. As there are limited natural plant sources for cis-9-tetradecenoic acid, the present invention aimed at the synthesis of cis-9-tetradecenoic acid methyl ester from oleic acid methyl ester. As oleic acid is not available in pure form, this has to be isolated from oleic acid-rich oils like olive oil. cis-10-Tetradecenoic acid methyl ester, an isomer of cis-9-tetradecenoic acid was also prepared from undecenoic acid methyl ester, a derivative of castor oil. Undecenoic acid is easily available commercially in pure form. Hexadecyl cis-9-tetradecenoate and hexadecyl c/s-10-tetradecenoate were prepared by enzymatic transesterification of cis-9-tetradecenoic acid methyl ester and cis-10-tetradecenoic acid methyl ester with 1-hexadecanol (cetyl alcohol) respectively. Both the isomers of cetyl myristoleate were evaluated for anti arthritis, blocking inflammation and reduction of adjuvant-induced arthritis in rats.

  十六烷基顺-9-十四碳烯酸盐通常被称为鲸蜡醇豆蔻酸酯（CMO），目前正被用于治疗骨关节炎和其他关节炎症疾病，顺-9-十四碳烯酸（顺-9-豆蔻酸）是制备CMO的主要前体。由于顺-9-十四碳烯酸的自然植物来源有限，本发明旨在从油酸甲酯合成顺-9-十四碳烯酸甲酯。由于油酸无法以纯净形式获得，因此需要从富含油酸的油类如橄榄油中提取。还从十一烯酸甲酯，即蓖麻油的衍生物，制备了顺-10-十四碳烯酸甲酯，这是顺-9-十四碳烯酸的异构体。十一烯酸在市场上容易以纯净形式获得。通过酶促转酯反应，分别用顺-9-十四碳烯酸甲酯和顺-10-十四碳烯酸甲酯与1-十六醇（鲸蜡醇）反应，制备了十六烷基顺-9-十四碳烯酸盐和十六烷基顺-10-十四碳烯酸盐。这两种鲸蜡醇豆蔻酸酯的异构体都进行了抗关节炎、阻断炎症和在大鼠中减少佐剂诱导关节炎的评价。
• [EN] RESORCINOL N-ARYL AMIDE COMPOUNDS, FOR USE AS PYRUVATE DEHYDROGENASE KINASE INHIBITORS<br/>[FR] COMPOSÉS DE RÉSORCINOL N-ARYLAMIDE DESTINÉS À ÊTRE UTILISÉS COMME INHIBITEURS DE PYRUVATE DÉSHYDROGÉNASE KINASE
  申请人：VERNALIS R & D LTD

  公开号：WO2015040425A1

  公开（公告）日：2015-03-26

  A compound of formula I: or a pharmaceutically acceptable salt thereof, wherein: Y is –CONR1- or optionally substituted arylene or optionally substituted heteroarylene; R1 is H, Cl, F, CH3 or CF3; 10 each R4 is independently H, CH3 or F; R5 is H or CH3; and each R2 and R6 is independently (Alk)n-Rn-(Alk)n-Rn-(Alk)n-X; The compounds of the invention are useful as resorcinol N-aryl amide (NAA) compounds, which are suitable for use as PDK inhibitors, for example for 15 inhibition of cancer cell proliferation.

  一种具有以下结构的化合物：或其药用可接受的盐，其中：Y为–CONR1-或可选择地取代的芳基或可选择地取代的杂芳基；R1为H、Cl、F、CH3或CF3；每个R4独立地为H、CH3或F；R5为H或CH3；每个R2和R6独立地为(Alk)n-Rn-(Alk)n-Rn-(Alk)n-X；该发明的化合物可用作间苯二酚N-芳基酰胺（NAA）化合物，适用于用作PDK抑制剂，例如用于抑制癌细胞增殖。
• [EN] SUCCINATE AND MALONATE SALT OF TRANS-4-(IR,3S)-6-CHLORO-3-PHENYLINDAN-1-YL)-1,2,2-TRIMETHYLPIPERAZINE AND THE USE AS A MEDICAMENT<br/>[FR] SEL DE SUCCINATE ET DE MALONATE DE TRANS-4-((1R,3S)-6-CHLORO-3-PHENYLINDAN-1-YL)-1,2,2-TRIMETHYLPIPERAZINE ET SON UTILISATION EN TANT QUE MEDICAMENT
  申请人：LUNDBECK & CO AS H

  公开号：WO2005016900A1

  公开（公告）日：2005-02-24

  4-((1R,3S)-6-Chloro-3-phenylindan-1-yl)-1,2,2-trimethylpiperazine hydrogen succinate or hadrogen malonat, pharmaceutical compositions containing these salts and the medical use thereof, including for the treatment of schizophrenia and other psychotic disorders. Also described are methods for the preparation of 4-((1R,3S)-6-Chloro-3-phenylindan-1-yl)-1,2,2-trimethylpiperazine and medical uses thereof.

  4-((1R,3S)-6-氯-3-苯基茚-1-基)-1,2,2-三甲基哌嗪氢丁二酸盐或氢丁二酸盐，含有这些盐的药物组合物及其医疗用途，包括用于治疗精神分裂症和其他精神疾病。还描述了制备4-((1R,3S)-6-氯-3-苯基茚-1-基)-1,2,2-三甲基哌嗪和其医疗用途的方法。